Cargando…

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape

PURPOSE: Hypodensity of pancreatic ductal adenocarcinoma (PDAC) during contrast-enhanced computed tomography (CECT) examination is common, but a minority of PDAC patients exhibit hyperdense images. The present study examined the clinical characteristics and protein landscape of PDAC with hyperdensit...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, He, Hua, Jie, Meng, Qingcai, Wang, Xiaohong, Xu, Jin, Wang, Wei, Zhang, Bo, Liu, Jiang, Liang, Chen, Yu, Xianjun, Shi, Si
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947874/
https://www.ncbi.nlm.nih.gov/pubmed/33718237
http://dx.doi.org/10.3389/fonc.2021.640820
_version_ 1783663317802287104
author Xu, He
Hua, Jie
Meng, Qingcai
Wang, Xiaohong
Xu, Jin
Wang, Wei
Zhang, Bo
Liu, Jiang
Liang, Chen
Yu, Xianjun
Shi, Si
author_facet Xu, He
Hua, Jie
Meng, Qingcai
Wang, Xiaohong
Xu, Jin
Wang, Wei
Zhang, Bo
Liu, Jiang
Liang, Chen
Yu, Xianjun
Shi, Si
author_sort Xu, He
collection PubMed
description PURPOSE: Hypodensity of pancreatic ductal adenocarcinoma (PDAC) during contrast-enhanced computed tomography (CECT) examination is common, but a minority of PDAC patients exhibit hyperdense images. The present study examined the clinical characteristics and protein landscape of PDAC with hyperdensity. MATERIALS AND METHODS: A total of 844 pathologically confirmed PDAC patients who underwent CECT before surgery were included. During the parenchymal phase of CECT, patients were assigned to the hyperdense or hypodense group based on CT values. Clinical and CT characteristics for predicting relapse-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan–Meier method and Cox proportional hazards model. The expression of the tumor angiogenesis marker CD31 and stroma-related protein CTHRC1 were analyzed using immunohistochemistry (IHC) assay to evaluate differences between the two groups. Proteomics was performed to compare the possible mechanisms underlying the differential enhancement on CT scans. RESULTS: Based on CECT, 43 and 801 PDAC patients had hyperdense and hypodense lesions, respectively. All 43 patients presented a hyperdense lesion in the parenchymal phase. The mean CECT values of the hyperdense group were higher than the hypodense group (102.5 ± 17.4 and 53.7 ± 18.7, respectively, P < 0.001). The hyperdense group had a better prognosis than the hypodense group (median RFS, 19.97 vs. 12.34 months, P = 0.0176; median OS, 33.6 vs. 20.3 months, P = 0.047). Multivariate analysis showed that age, higher CA19-9 levels (> 300 U/ml), tumor stage, tumor differentiation, tumor CT density, and adjuvant chemotherapy were significant independent prognostic factors for OS. CD31 immunohistochemical staining showed that the hyperdense PDACs had a higher microvessel density than the hypodense group (P < 0.001). CTHRC1 expression was higher in the hypodense group (P = 0.019). Sixty-eight differentially expressed proteins were found using the tandem mass tag labeling-based quantification of the proteomes of PDAC tissue samples, and 7 proteins (POFUT1, PKP2, P0DOX4, ITPR1, HBG2, IGLC3, SAA2) were related to angiogenesis. CONCLUSION: Patients who presented with a hyperdense mass on CECT had a higher microvessel density and better prognosis. Anti-angiogenic therapy may be suitable for these patients.
format Online
Article
Text
id pubmed-7947874
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79478742021-03-12 Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape Xu, He Hua, Jie Meng, Qingcai Wang, Xiaohong Xu, Jin Wang, Wei Zhang, Bo Liu, Jiang Liang, Chen Yu, Xianjun Shi, Si Front Oncol Oncology PURPOSE: Hypodensity of pancreatic ductal adenocarcinoma (PDAC) during contrast-enhanced computed tomography (CECT) examination is common, but a minority of PDAC patients exhibit hyperdense images. The present study examined the clinical characteristics and protein landscape of PDAC with hyperdensity. MATERIALS AND METHODS: A total of 844 pathologically confirmed PDAC patients who underwent CECT before surgery were included. During the parenchymal phase of CECT, patients were assigned to the hyperdense or hypodense group based on CT values. Clinical and CT characteristics for predicting relapse-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan–Meier method and Cox proportional hazards model. The expression of the tumor angiogenesis marker CD31 and stroma-related protein CTHRC1 were analyzed using immunohistochemistry (IHC) assay to evaluate differences between the two groups. Proteomics was performed to compare the possible mechanisms underlying the differential enhancement on CT scans. RESULTS: Based on CECT, 43 and 801 PDAC patients had hyperdense and hypodense lesions, respectively. All 43 patients presented a hyperdense lesion in the parenchymal phase. The mean CECT values of the hyperdense group were higher than the hypodense group (102.5 ± 17.4 and 53.7 ± 18.7, respectively, P < 0.001). The hyperdense group had a better prognosis than the hypodense group (median RFS, 19.97 vs. 12.34 months, P = 0.0176; median OS, 33.6 vs. 20.3 months, P = 0.047). Multivariate analysis showed that age, higher CA19-9 levels (> 300 U/ml), tumor stage, tumor differentiation, tumor CT density, and adjuvant chemotherapy were significant independent prognostic factors for OS. CD31 immunohistochemical staining showed that the hyperdense PDACs had a higher microvessel density than the hypodense group (P < 0.001). CTHRC1 expression was higher in the hypodense group (P = 0.019). Sixty-eight differentially expressed proteins were found using the tandem mass tag labeling-based quantification of the proteomes of PDAC tissue samples, and 7 proteins (POFUT1, PKP2, P0DOX4, ITPR1, HBG2, IGLC3, SAA2) were related to angiogenesis. CONCLUSION: Patients who presented with a hyperdense mass on CECT had a higher microvessel density and better prognosis. Anti-angiogenic therapy may be suitable for these patients. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7947874/ /pubmed/33718237 http://dx.doi.org/10.3389/fonc.2021.640820 Text en Copyright © 2021 Xu, Hua, Meng, Wang, Xu, Wang, Zhang, Liu, Liang, Yu and Shi http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xu, He
Hua, Jie
Meng, Qingcai
Wang, Xiaohong
Xu, Jin
Wang, Wei
Zhang, Bo
Liu, Jiang
Liang, Chen
Yu, Xianjun
Shi, Si
Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
title Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
title_full Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
title_fullStr Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
title_full_unstemmed Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
title_short Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
title_sort hyperdense pancreatic ductal adenocarcinoma: clinical characteristics and proteomic landscape
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947874/
https://www.ncbi.nlm.nih.gov/pubmed/33718237
http://dx.doi.org/10.3389/fonc.2021.640820
work_keys_str_mv AT xuhe hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT huajie hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT mengqingcai hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT wangxiaohong hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT xujin hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT wangwei hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT zhangbo hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT liujiang hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT liangchen hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT yuxianjun hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape
AT shisi hyperdensepancreaticductaladenocarcinomaclinicalcharacteristicsandproteomiclandscape